14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $14.58 $20.11 Thursday, 2nd May 2024 DNLI stock ended at $16.81. This is 4.02% more than the trading day before Wednesday, 1st May 2024. During the day the stock fluctuated 6.41% from a day low at $15.92 to a day high of $16.94.
90 days $14.58 $23.52
52 weeks $14.58 $33.31

Historical Denali Therapeutics Inc. prices

Date Open High Low Close Volume
Nov 01, 2023 $18.82 $19.09 $18.55 $19.03 870 791
Oct 31, 2023 $18.33 $18.85 $17.98 $18.83 570 014
Oct 30, 2023 $18.38 $19.04 $18.23 $18.40 545 303
Oct 27, 2023 $19.29 $19.29 $18.07 $18.20 996 680
Oct 26, 2023 $19.78 $19.89 $19.16 $19.28 734 528
Oct 25, 2023 $19.46 $20.10 $19.31 $19.64 930 583
Oct 24, 2023 $18.86 $19.74 $18.86 $19.70 970 866
Oct 23, 2023 $18.37 $18.91 $18.24 $18.70 639 828
Oct 20, 2023 $18.80 $18.80 $18.09 $18.32 1 065 389
Oct 19, 2023 $19.30 $19.35 $18.66 $18.88 643 104
Oct 18, 2023 $20.42 $20.42 $19.26 $19.33 596 507
Oct 17, 2023 $20.69 $21.33 $20.56 $20.58 580 411
Oct 16, 2023 $20.66 $20.97 $20.17 $20.75 456 754
Oct 13, 2023 $20.52 $20.76 $20.10 $20.76 754 779
Oct 12, 2023 $21.49 $21.61 $20.15 $20.51 625 037
Oct 11, 2023 $21.59 $21.95 $21.16 $21.48 435 941
Oct 10, 2023 $20.99 $21.88 $20.93 $21.65 779 463
Oct 09, 2023 $20.71 $21.14 $20.34 $20.99 845 602
Oct 06, 2023 $20.79 $21.20 $20.52 $20.91 593 776
Oct 05, 2023 $20.39 $21.26 $20.20 $21.14 828 894
Oct 04, 2023 $20.72 $20.85 $19.83 $20.62 861 333
Oct 03, 2023 $19.62 $20.76 $19.57 $20.75 1 009 257
Oct 02, 2023 $20.53 $20.53 $19.67 $19.79 1 568 577
Sep 29, 2023 $21.04 $21.04 $20.52 $20.63 860 603
Sep 28, 2023 $21.50 $21.71 $20.82 $20.96 566 726
Click to get the best stock tips daily for free!

About Denali Therapeutics Inc.

Denali Therapeutics. Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for ... DNLI Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT